U.S. Home Infusion Therapy Market Size Touched USD 21.52 Billion in 2025; Long-Term Management of Chronic and Complex Diseases to Drive the Market’s Upward Momentum

The global U.S. home infusion therapy market size in 2025 was valued at USD 21.52 billion. The market value is predicted to grow from USD 23.58 billion in 2026 to USD 49.83 billion by 2034, with a CAGR of 9.81% from 2026 to 2034. Fortune Business Insights™ presents this information in its report titled “U.S. Home Infusion Therapy Market Size, Share & Industry Analysis, By Product (Devices {Durable Medical Equipment/Pumps and Consumables & Accessories}, Drugs {Small Molecule/Conventional Infused Drugs, Biologics & Plasma-Derived Therapies, and Nutrition Products}, and Services {Pharmacy Services, Nursing & Clinical Services, Logistic & Care Coordination, and Training & Monitoring Services}), By Indication (Enteral Nutrition, Anti-Infective, Chemotherapy, Hydration Therapy, Total Parenteral Nutrition, Immunoglobulins, and Others), and Regional Forecast, 2026-2034”.

The market for home infusion therapy in the U.S., is driven by the need to shift patients from hospitals to home-based care. As per the data published by NIHCM Foundation in April 2025, it has been reported that approximately 6 in 10 Americans live with at least one chronic disease.  This creates a large patient pool for recurring treatment and long-term care support. Furthermore, the need for immunoglobulin and nutrition support and requirement for long-term management of chronic and complex diseases is constantly pushing the demand for home infusion therapies in the U.S. There has been a growing demand for home-based IVIG, anti-infectives, parenteral nutrition, enteral nutrition, hydration support, and specialty biologics, as patients and healthcare providers look for treatment alternatives beyond hospitals.

Paragon Healthcare Partnered With Brightstar Care For Providing Home Infusion Services

In January 2024, Paragon Healthcare joined hands with BrightStar Care for its premier partnership for home infusion services. The partnership was aimed at supporting Paragon’s “IV Anywhere” model across home infusion, infusion centers, and specialty pharmacies, while using BrightStar Care’s national home care and nursing network to expand access to home infusion services. This partnership is set to combine Paragon’s infusion capabilities and BrightStar Care’s nurse-led, Joint Commission-accredited care model. 

Therapy Diversity and Shift towards Traditional Anti-Infective Care to Drive the Market Growth Trajectory

The market is moving beyond traditional anti-infective care as providers are aiming for a wider mix of home enteral nutrition, parenteral nutrition, immune globulin, specialty infusion, hydration, and other chronic therapies.  For this, therapy diversity, one of the key trends shaping the trajectory of the market, is gaining traction. The trend is supported by requirement for long-term specialty therapies for immune deficiencies, autoimmune disorders, GI diseases, infections, and complex chronic conditions, where patients often prefer lower-cost and more convenient care outside hospitals.

On the contrary, the U.S. home infusion therapy market growth is hampered by safety risks associated and clinical complexities as these therapies, outside a hospital environment, require safe handling of drugs, vascular access devices, pumps, tubing, catheters, and sterile supplies.

Key Players are Cementing Their Market Positions Through Extensive Service Networks and Partnerships

The U.S. home infusion therapy market has major providers including Option Care Health, Optum Inc., and CVS Health that have a considerable market presence owing to broad service networks, specialty pharmacy capabilities, home infusion pharmacies, and care coordination platforms. Other market players KabaFusion, CareCentrix, Inc., PromptCare Respiratory, Baxter, InfuSystem Holdings, Inc., and Moog Inc., among others are focusing on geographical expansion, payer partnerships, specialty therapy range, home nursing support, digital referral workflows, and infusion-suite networks.

Key Players Profiled in the Report

• Option Care Health Inc. (U.S.)
• Optum Inc. (U.S.)
• CareCentrix Inc. (U.S.)
• CVS Health (U.S.)
• KabaFusion (U.S.)
• Promptcare Respiratory (U.S.)
• Baxter (U.S.)
• InfuSystem Holdings, Inc. (U.S.)
• Moog Inc. (U.S.)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/u-s-home-infusion-therapy-market-106327

Key Industry Development

• May 2024: Rockfield Medical Devices received the U.S. FDA over-the-counter clearance for its Mobility+ Enteral Feeding System.

Further Report Findings

• West U.S. took the leading share of the country in 2025 owing to the presence of advanced healthcare systems, specialty-care providers, and home health networks. In California, Washington, Arizona, Colorado, Nevada, and Oregon there is a higher adoption of home-based chronic therapy models. Along with this, South U.S. is expected to grow at a CAGR of 9.98% during the forecast period.
• By product, drugs captured the highest U.S. home infusion therapy market share owing to high usage of immunoglobulins, specialty biologics, anti-infectives, chemotherapy drugs, hydration solutions, and parenteral nutrition formulations in home and alternate-site care.
• As per indication, enteral nutrition segment led the market due to patients requiring long-term nutritional assistance at home owing to dysphagia, neurological issues, cancer, gastrointestinal ailments, and various other chronic conditions.

Table of Segmentation